Latest Period
Q1 2026
Security Snapshot
Fulcrum Therapeutics, Inc. - Common stock, par value $0.001 per share (FULC) Institutional Ownership
CUSIP: 359616109
13F Institutional Holders and Ownership History from Q3 2019 to Q1 2026
Institutions Reporting
168
Shares (Excl. Options)
71,717,008
Price
$7.67
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common stock, par value $0.001 per share
- Symbol
- FULC on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 71,717,008
- Total 13F value
- $550,141,537
- Portfolio coverage rank
- 0%
- Share change
- +2,396,184
- Value change
- +$6,375,487
- Number of holders
- 168
- Shares outstanding
- 66,594,760
- SEC-reported price per share
- $6.96
- Insider filing price
- $6.96
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- FULC - Fulcrum Therapeutics, Inc. - Common stock, par value $0.001 per share is tracked under CUSIP 359616109.
- 168 institutions reported positions in Q1 2026.
- 6 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 173 to 168 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $762,744,189 to $550,141,537.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 168 institutions filings for Q1 2026.
Security key
359616109
Latest holder period
Q1 2026
13F holders
168
13D/G owners
6
CIK / CUSIP context first
Open Q1 2026 holders
FULC full holder history
Fulcrum Therapeutics, Inc. SEC filings
Fulcrum Therapeutics, Inc. company facts
Fulcrum Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 359616109:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
6
Security
FULC
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 9.9% | -12% | $67,231,227 | +$6,025,691 | 6,649,973 | +9.8% | RA Capital Management, L.P. | 31 Dec 2025 |
| TCG Crossover GP II, LLC | 7.9% | $40,267,500 | 5,250,000 | TCG Crossover GP II, LLC | 31 Mar 2026 | |||
| SUVRETTA CAPITAL MANAGEMENT, LLC | 9.4% | +52% | $18,495,988 | +$6,069,154 | 5,067,394 | +49% | SUVRETTA CAPITAL MANAGEMENT, LLC | 31 Mar 2025 |
| BlackRock, Inc. | 6% | -19% | $30,090,560 | -$7,016,336 | 3,270,322 | -19% | BlackRock, Inc. | 30 Sep 2025 |
| Nantahala Capital Management, LLC | 4.6% | -38% | $23,393,807 | -$13,252,778 | 3,050,040 | -36% | Nantahala Capital Management, LLC | 31 Mar 2026 |
| Adage Capital Management, L.P. | 4.5% | -44% | $22,374,400 | -$19,844,400 | 2,432,000 | -47% | Adage Capital Management, L.P. | 30 Sep 2025 |
As of 31 Mar 2026, 168 institutional investors reported holding 71,717,008 shares of Fulcrum Therapeutics, Inc. - Common stock, par value $0.001 per share (FULC). This represents 108% of the company’s total 66,594,760 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
90%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, LLC | 9.9% | 6,561,111 | 0% | 1.4% | $50,323,721 |
| RA CAPITAL MANAGEMENT, L.P. | 9.1% | 6,053,960 | 0% | 0.49% | $46,433,873 |
| BlackRock, Inc. | 8.1% | 5,390,593 | +26% | 0% | $41,345,848 |
| TCG Crossover Management, LLC | 7.9% | 5,250,000 | 0% | 1.2% | $40,267,500 |
| BRAIDWELL LP | 4.7% | 3,134,922 | +2.4% | 0.8% | $24,044,852 |
| Nantahala Capital Management, LLC | 4.6% | 3,050,040 | -29% | 1.5% | $23,393,807 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4% | 2,692,948 | 0% | 0% | $20,654,911 |
| Siren, L.L.C. | 3.5% | 2,350,000 | +21% | 0.5% | $18,024,500 |
| First Turn Management, LLC | 3.4% | 2,256,109 | +19% | 1.9% | $17,304,356 |
| Aberdeen Group plc | 3.3% | 2,211,953 | +76% | 0.03% | $16,965,680 |
| Point72 Asset Management, L.P. | 3.1% | 2,074,855 | -13% | 0.03% | $15,914,138 |
| GSK plc | 2.7% | 1,785,714 | 0% | 2.3% | $13,696,426 |
| Balyasny Asset Management L.P. | 2.7% | 1,779,946 | +83% | 0.03% | $13,652,186 |
| Jones Hill Capital LP | 2.7% | 1,771,926 | 0% | 2.9% | $13,590,672 |
| D. E. Shaw & Co., Inc. | 2.4% | 1,623,281 | -15% | 0.01% | $12,450,565 |
| STATE STREET CORP | 2.3% | 1,549,851 | +54% | 0% | $11,887,357 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.2% | 1,486,542 | +34% | 0% | $11,403,881 |
| Alyeska Investment Group, L.P. | 2% | 1,328,449 | 0.03% | $10,189,204 | |
| CITADEL ADVISORS LLC | 1.9% | 1,292,486 | +7.1% | 0.01% | $9,913,368 |
| Assenagon Asset Management S.A. | 1.8% | 1,193,873 | 0.01% | $9,157,006 | |
| DIMENSIONAL FUND ADVISORS LP | 1.7% | 1,130,281 | +7.5% | 0% | $8,663,440 |
| Vestal Point Capital, LP | 1.7% | 1,100,000 | +16% | 0.24% | $8,437,000 |
| Ikarian Capital, LLC | 1.6% | 1,049,161 | -24% | 1.2% | $8,047,065 |
| Qube Research & Technologies Ltd | 1.5% | 974,739 | +148% | 0.01% | $7,476,248 |
| Connor, Clark & Lunn Investment Management Ltd. | 1.1% | 736,684 | +26% | 0.01% | $5,650,366 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
27
Latest
Q1 2026
Rows shown
1-25 of 27
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 71,717,008 | $550,141,537 | +$6,375,487 | $7.67 | 168 |
| 2025 Q4 | 67,444,423 | $762,744,189 | +$134,984,797 | $11.31 | 173 |
| 2025 Q3 | 53,790,538 | $494,909,349 | -$1,273,053 | $9.20 | 127 |
| 2025 Q2 | 54,400,644 | $374,498,177 | +$23,533,452 | $6.88 | 122 |
| 2025 Q1 | 51,307,184 | $147,764,693 | -$3,070,431 | $2.88 | 115 |
| 2024 Q4 | 51,666,381 | $242,831,448 | -$8,308,464 | $4.70 | 117 |
| 2024 Q3 | 54,857,560 | $195,845,950 | -$86,380,213 | $3.57 | 127 |
| 2024 Q2 | 64,752,304 | $401,470,762 | +$19,716,085 | $6.20 | 120 |
| 2024 Q1 | 60,342,845 | $569,639,654 | -$2,974,963 | $9.44 | 122 |
| 2023 Q4 | 61,083,723 | $412,326,970 | +$14,153,071 | $6.75 | 100 |
| 2023 Q3 | 56,394,454 | $250,394,156 | +$9,019,379 | $4.44 | 79 |
| 2023 Q2 | 55,518,138 | $183,197,485 | -$14,257,183 | $3.30 | 85 |
| 2023 Q1 | 60,413,854 | $172,155,022 | +$51,602 | $2.85 | 115 |
| 2022 Q4 | 50,644,890 | $368,693,025 | -$13,010,376 | $7.28 | 109 |
| 2022 Q3 | 52,209,184 | $422,360,458 | +$98,764,326 | $8.09 | 104 |
| 2022 Q2 | 40,127,745 | $196,621,873 | -$32,729,118 | $4.90 | 97 |
| 2022 Q1 | 39,071,704 | $923,864,555 | +$64,674,079 | $23.65 | 104 |
| 2021 Q4 | 37,197,291 | $657,236,909 | -$42,835,792 | $17.69 | 107 |
| 2021 Q3 | 36,552,286 | $1,031,536,477 | +$305,128,643 | $28.21 | 100 |
| 2021 Q2 | 26,798,436 | $280,833,000 | -$3,275,840 | $10.48 | 66 |
| 2021 Q1 | 26,913,060 | $317,031,000 | +$45,552,581 | $11.78 | 68 |
| 2020 Q4 | 22,170,825 | $259,615,000 | +$20,231,071 | $11.71 | 65 |
| 2020 Q3 | 20,593,739 | $163,306,000 | -$36,882,837 | $7.93 | 53 |
| 2020 Q2 | 20,455,938 | $373,550,782 | +$66,390,720 | $18.29 | 60 |
| 2020 Q1 | 16,827,383 | $200,921,119 | +$11,941,010 | $11.94 | 46 |